Výsledky léčby gefitinebem (Iressou) u 89 nemocných s pokročilým nemalobuněčným karcinomem plic (NSCLC)

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Results of gefitinib (Iressa) treatment of 89 patients with advanced non-small cell lung cancer (NSCLC)
Authors

SKŘIČKOVÁ Jana TOMÍŠKOVÁ Marcela SVOBODNÍK Adam KAPLANOVÁ Jana PÁLKOVÁ Ivana KADLEC Bohdan BABIČKOVÁ Lenka STRATIL Dalibor NEBESKÝ Tomáš

Year of publication 2005
Type Article in Proceedings
Conference Edukační sborník
MU Faculty or unit

Faculty of Medicine

Citation
Field Pneumology
Keywords non-small cell lung cancer (NSCLC); treatment; gefinitib
Description The results of the first 89 NSCLC patients treated with gefinitib (Iressa)are presented. The treatment started between Feb 2002 and Aug 2004 In Jan 2005, the median survival was 10.3 months in the group with perfomance status 1. In 39% (44 pats) stabilization was achieved, in 8 (9%) partial remission was confirmed. Complete remission occurred in none. Overall, the tolerance of the drug was very good.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info